SynthesisPloS one2016
Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Prognostic value of SPARC in hepatocellular carcinoma: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review.Frontiers in oncology · 2020Pooled it
- Stromal secreted protein acidic and rich in cysteine expression: A potential target for improved prognosis in patients with pancreatic cancer.World journal of gastrointestinal oncology · 2025Article
- Proteomics in pancreatic cancer.Biomarker research · 2025Review
- Progress on diagnostic and prognostic markers of pancreatic cancer.Oncology research · 2023Review
- Mesenchymal stem cells induce tumor stroma formation and epithelial‑mesenchymal transition through SPARC expression in colorectal cancer.Oncology reports · 2021Observational
- Targeting the Stroma in the Management of Pancreatic Cancer.Frontiers in oncology · 2021Review
- Proton therapy delivery: what is needed in the next ten years?The British journal of radiology · 2020Review
- Article
- Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma.BMC cancer · 2019Article
- Advances in pancreatic cancer biomarkers.Oncology reviews · 2019Article
- PRPF40A as a potential diagnostic and prognostic marker is upregulated in pancreatic cancer tissues and cell lines: an integrated bioinformatics data analysis.OncoTargets and therapy · 2019Article
- The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection.Journal of Cancer · 2019Article
- Proteomic Identification and Time-Course Monitoring of Secreted Proteins During Expansion of Human Mesenchymal Stem/Stromal in Stirred-Tank Bioreactor.Frontiers in bioengineering and biotechnology · 2019Article
- INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT.OncoTargets and therapy · 2019Article
- Shattering the castle walls: Anti-stromal therapy for pancreatic cancer.World journal of gastrointestinal oncology · 2018Review
- Prognostic value of SPARCL1 in patients with colorectal cancer.Oncology letters · 2018Article
- p-Akt as a potential poor prognostic factor for gastric cancer: a systematic review and meta-analysis.Oncotarget · 2017Review
- SPARC overexpression suppresses radiation-induced HSP27 and induces the collapse of mitochondrial Δψ in neuroblastoma cells.Oncology letters · 2017Article
- Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings.OncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere is a heated debate on whether the prognostic value of SPARC is favorable or unfavorable. Thus, we carried out a meta-analysis evaluating the relationship between SPARC expression and the prognosis of patients with pancreatic cancer.
methodsWe searched PubMed, EMBASE and Web of Science for relevant articles. The pooled hazard ratios (HRs) and corresponding 95%CI of overall survival (OS) were calculated to evaluate the prognostic value of SPARC expression in patients with pancreatic cancer. We also performed subgroup analyses.
resultsWith 1623 patients pooled from 10 available studies, the incorporative HR showed an unfavorable prognosis of patients with pancreatic cancer in the multivariate analysis (HR = 1.55, 95%CI: 1.11-2.17, P = 0.01), but not in univariate analysis (HR = 1.41, 95%CI: 0.47-4.21, P = 0.54) and estimate (HR = 1.24, 95%CI: 0.72-2.13, P = 0.44). And this adverse impact could also be found in the subgroup analyses in multivariate analysis, especially in the stroma (HR = 1.53, 95%CI: 1.05-2.24, P = 0.03). However, the combined HR had the highly significant heterogeneity. No obvious publication bias was found.
conclusionsSPARC might be an unfavorable indicator in patients with pancreatic cancer, especially in the stroma. More and further researches should be conducted to reveal the prognostic value of SPARC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.